Ra Medical Systems Appoints General Counsel

Ra Medical Systems Inc., a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, has appointed Dan Horwood as General Counsel, effective immediately. Horwood brings nearly two decades of corporate and securities experience to Ra Medical and will oversee all aspects of the company’s legal activities and policies.
 
“Dan’s experience advising publicly listed companies on corporate matters makes him an ideal and timely choice for Ra Medical. We welcome his guidance and counsel as part of our leadership team,” said Dean Irwin, CEO, Ra Medical Systems. “We believe Dan will be an invaluable asset to Ra Medical as our business continues to expand, especially with the continued rollout of our DABRA catheter and laser system across the U.S. and international markets.”
 
Horwood joins Ra Medical Systems from Teradata Corporation, where he served as counsel, Corporate and Transactions, and was responsible for advising on securities compliance issues and M&A activity. Prior to Teradata, he served as counsel for Wilson Sonsini Goodrich and Rosati, where he advised clients on public offerings, private financing, mergers and acquisitions, securities compliance, public company reporting and corporate governance. Over the years, Horwood worked at Groupon and BMO Capital Markets in roles of increasing responsibility. Horwood began his career at the United States Securities and Exchange Commission’s Division of Corporation Finance.
 
“I am excited to join the Ra Medical team at this pivotal moment in the company’s development,” said Horwood. “I look forward to working closely with the executive team at Ra Medical as we continue to expand the company’s commercial efforts for DABRA.”
 
Horwood has a J.D. from the University of Pennsylvania Law School.
 
Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatologic and vascular diseases. DABRA, launched in 2017, is used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. DABRA quickly, photochemically dissolves plaque to the components of its fundamental chemistry. Pharos launched in 2004 and is used as a tool in the treatment of dermatological skin disorders, including psoriasis and vitiligo.